Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Natl Compr Canc Netw ; 21(8): 821-830.e3, 2023 08.
Artigo em Inglês | MEDLINE | ID: mdl-37549911

RESUMO

BACKGROUND: Radiotherapy (RT) causes adverse events for which there are no effective treatments. This study investigated the clinical benefits of compound Kushen injection (CKI) in managing radiation injury in patients with lung cancer. METHODS: A multicenter, open-label, randomized clinical trial randomly assigned patients with lung cancer to receive either CKI (20 mL/d for at least 4 weeks) integrated with curative RT (RT + CKI group; n=130) or RT alone (control group; n=130). The primary outcome was the incidence of grade ≥2 radiation-induced lung injury (RILI) in the lungs, esophagus, or heart. Secondary outcomes included patient-reported symptoms, quality of life, objective response rate (ORR), and toxic effects. RESULTS: During the 16-week trial, the RT + CKI group had a significantly lower incidence of grade ≥2 RT-related injury than the control group (12.3% [n=16] vs 23.1% [n=30]; P=.02). Compared with the control group, the RT + CKI group experienced a significant decrease in moderate-to-severe symptoms of fatigue, cough, and pain (P<.001 for the treatment and time interaction term); significantly less physical symptom interference (P=.01); and significantly better quality of life by the end of the trial (P<.05). No statistically significant difference in ORR was found. Adverse reactions associated with CKI were rare. CONCLUSIONS: This study demonstrated low toxicity of CKI and its effectiveness in patients with lung cancer in reducing the incidence of grade ≥2 RILI and symptom burden, improving patients' quality of life.


Assuntos
Antineoplásicos , Medicamentos de Ervas Chinesas , Neoplasias Pulmonares , Humanos , Qualidade de Vida , Neoplasias Pulmonares/radioterapia , Neoplasias Pulmonares/tratamento farmacológico , Antineoplásicos/uso terapêutico , Medicamentos de Ervas Chinesas/efeitos adversos
2.
Org Lett ; 22(20): 7942-7946, 2020 Oct 16.
Artigo em Inglês | MEDLINE | ID: mdl-33021796

RESUMO

One-pot synthesis of a new doubly boron-doped polycyclic aromatic hydrocarbon of 6,12-dimesityl-6,12-dihydro-6,12-diboradibenzo[def,mno]chrysene (MDBDBC) was reported. MDBDBC features a rigid planar electron-deficient core structure and demonstrates good chemical and thermal stabilities. A low-lying LUMO of -3.53 eV, a low locally excited triplet energy of 1.92 eV, as well as green electroluminescence with maximum EQE of 4.9% were found for MDBDBC, suggesting its potential as an n-type unit for future organic light emitting diode applications.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...